Global leader in high-validity real-world evidence for life sciences among select few who have achieved Inc. 5000 Honor Roll status
MENLO PARK, Calif.–(BUSINESS WIRE)–Verantos today announced it has achieved Honor Roll status, ranking on the Inc. 5000 list for the fifth consecutive year. Fewer than 10% of Inc. 5000 companies reach the list five times or more. The list is the most prestigious ranking of the nation’s most successful independent and entrepreneurial businesses, recognizing companies that have achieved remarkable growth while driving innovation, creating jobs, and shaping the future of the economy. Verantos ranked No. 2961 on this year’s list. Past honorees include companies such as Microsoft, Meta, Chobani, Oracle, and Patagonia.
“Joining the Inc. 5000 Honor Roll recognizes a pattern of growth that Verantos has sustained since 2018,” said Dan Riskin, MD, CEO of Verantos. “Our ranking this year reflects continued demand from life sciences organizations for clinically rich, high-validity real-world evidence.”
This year’s Inc. 5000 recognizes a new class of companies redefining what growth looks like. From AI and advanced manufacturing to healthcare, consumer products, and professional services, these businesses are expanding their impact, creating jobs and proving that entrepreneurial ambition continues to fuel the U.S. economy. Among the 5,000 companies on the list, the median three-year revenue growth rate was 130%, and those companies have collectively added more than 627,208 jobs to the U.S. economy over the past three years.
“Every company on the Inc. 5000 has a story of perseverance, smart decision making, and a refusal to sit still,” says Mike Hofman, editor-in-chief of Inc. “Their growth reflects more than strong financial performance–it reflects creativity, resilience, and the customer focus required to build companies that make a lasting impact. We congratulate all honorees on this significant achievement.”
Inc. 5000 List Methodology
Companies on the 2026 Inc. 5000 are ranked according to percentage revenue growth from 2022 to 2025. To qualify, companies must have been founded and generating revenue by March 31, 2022. They must be U.S.-based, privately held, for-profit, and independent — not subsidiaries or divisions of other companies — as of December 31, 2025. Since then, some on the list may have gone public or been acquired. The minimum revenue required for 2022 is $100,000; the minimum for 2025 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons.
About Inc.
Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit www.inc.com.
About Verantos
Verantos is transforming pharmacoepidemiology by providing the highest quality real-world data augmented by curation and clinical inference, and agentic AI tools to generate high-validity evidence at a fraction of the current cost and time. The Verantos pharmacoepidemiology stack advances evidence generation beyond traditional HEOR, supporting clinical development, comparative effectiveness, regulatory, label expansion, safety, and post-marketing commitments. Learn more at verantos.com.
Contacts
Media contact:
Dan West, VP Marketing, Verantos
[email protected]
